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Aim: We report results of a first-in-human study of pasotuxizumab, a PSMA bispecific T-cell engager
(BiTE R©) immune therapy mediating T-cell killing of tumor cells in patients with advanced castration-
resistant prostate cancer. Patients & methods: We assessed once-daily subcutaneous (SC) pasotuxizumab.
All SC patients developed antidrug antibodies; therefore, continuous intravenous (cIV) infusion was as-
sessed. Results: A total of 47 patients received pasotuxizumab (SC: n = 31, 0.5–172 μg/d; cIV: n = 16, 5–
80 μg/d). The SC maximum tolerated dose was 172.0 μg/d. A sponsor change stopped the cIV cohort early;
maximum tolerated dose was not determined. PSA responders occurred (>50% PSA decline: SC, n = 9; cIV,
n = 3), including two long-term responders. Conclusion: Data support pasotuxizumab safety in advanced
castration-resistant prostate cancer and represent evidence of BiTE monotherapy efficacy in solid tumors.
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Patients with advanced metastatic castration-resistant prostate cancer (mCRPC) have a poor prognosis [1]; although
many treatment options are available, treatment effects are transient and survival benefits are limited [2]. Immune
checkpoint inhibitors, BiTE R© (bispecific T-cell engager) immune therapies and chimeric antigen receptor (CAR)
T cells have been approved for certain cancer types over the last decade [3–12]. However, the role of BiTE molecules
or CAR T cell approaches in solid cancers is still unclear, including in patients with mCRPC. PSMA is expressed
in the epithelial cells of a variety of normal tissues, including the prostate, urinary bladder and proximal tubules
of the kidney [13]; however, its expression is much higher in prostate cancer and its metastates [13–15] and, thus,
is a compelling therapeutic target [14,16]. Lutetium-177 (177Lu)-PSMA-617, a radionuclide treatment that binds
to PSMA, has antitumor activity [16–19], thus validating PSMA as a target for therapy in mCRPC. Additionally,
gallium-68 (68Ga)-PSMA-11 is a common positron emission tomographic (PET) imaging tracer used to detect
PSMA [20].
Immune checkpoint inhibitors have not shown efficacy in most patients with mCRPC, likely as a result of the
heterogeneous and immune suppressive microenvironment in prostate cancer. Early studies with antiprogrammed
death 1 (PD-1) antibody monotherapy showed limited efficacy in patients with prostate cancer [21], with recent
reports suggesting that only certain subsets of patients benefit [22]. Similarly, a recent study reported that the cytotoxic
T-lymphocyte–associated inhibitor ipilimumab may be effective in certain subsets of patients with mCRPC [23];
however, it failed to show significant survival benefit and was associated with higher rates of severe adverse effects in
an unselected population [24]. A recent study found that addition of the antiprogrammed death-ligand 1 antibody
atezolizumab to the androgen receptor antagonist enzalutamide did not show any benefit in terms of overall survival
versus enzalutamide alone [25].
Pasotuxizumab (also known as AMG 212 or BAY 2010112), a 55 kDa BiTE immune therapy, is designed to
engage CD3 on T cells and PSMA on prostate cancer cells, thereby activating a patient’s own T cells to eliminate
PSMA-expressing prostate cancer cells. In preclinical studies, pasotuxizumab was shown to bind to PSMA-expressing
human cells and to human T cells and to trigger antigen-dependent target cell lysis, T-cell activation and cytokine
release [26]. In human prostate cancer cell lines, pasotuxizumab-directed T cells resulted in cell lysis at half-maximal
effective concentrations (EC50) between 0.1 and 4 ng/ml (1.8 and 72 pmol/l) [26]. Moreover, pasotuxizumab
delayed tumor growth and led to tumor shrinkage and remission in human prostate cancer xenograft models [26].
This Phase I, open-label, dose-escalation study of pasotuxizumab was undertaken in patients with advanced
CRPC. The primary objective was to determine the safety and maximum tolerated dose (MTD) of pasotuxizumab
administered by subcutaneous (SC) injection or continuous intravenous (cIV) infusion. Secondary objectives
included evaluation of the pharmacokinetics, PSA and radiographic tumor response; exploratory objectives included
the evaluation of biomarkers, such as circulating tumor cells (CTCs) and radio-imaging.
Materials & methods
Patients
Men aged ≥18 years with histologically or cytologically confirmed advanced CRPC with treatment failure after ≥1
taxane regimen and who were refractory to abiraterone and/or enzalutamide or refused any other standard therapy
were eligible for inclusion in the study. Eligible patients had undergone bilateral orchiectomy or received continuous
androgen deprivation therapy and had evidence of progressive disease after discontinuation of anti-androgen therapy
(i.e., flutamide, bicalutamide or nilutamide) before study drug treatment; had an Eastern Cooperative Oncology
Group performance status of 0–2; had life expectancy of ≥3 months; and had adequate bone marrow, liver and renal
function. Key exclusion criteria included confirmed prior or current autoimmune disease, any antitumor therapy or
immunotherapy within 4 weeks of the first pasotuxizumab dose (with the exception of denosumab, bisphosphonates
and gonadotropin-releasing hormone agonists or antagonists), or history of symptomatic metastatic brain or
meningeal tumors (unless the patient had not received definitive therapy for >3 months and had no evidence
of tumor growth within 2 weeks of study entry). The study was conducted in accordance with Good Clinical
Practice guidelines and the Declaration of Helsinki. The study protocol was approved by the institutional review
boards/ethics committees at each study site; all patients provided written informed consent.
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Study design
This was an open-label, multicenter, Phase I, dose-escalation study (ClinicalTrials.gov, NCT01723475) conducted
at five clinical study centers in Germany and Austria and sponsored by Bayer AG, Leverkusen, Germany. It was
designed to determine the safety and MTD of pasotuxizumab (primary objectives) and to assess pharmacokinetics,
PSA and tumor response (secondary objectives) and biomarkers (exploratory objective) of pasotuxizumab admin-
istered either by daily SC injection or cIV infusion. An independent data monitoring committee was established
to regularly review safety data. The starting doses for the SC and cIV cohorts were 0.5 and 5 μg daily, respectively.
The MTD was defined as the maximum dose at which <20% of patients in a cohort had dose-limiting toxicities
(DLTs) in cycle 1 (i.e., days 1–21). Initially, single-patient SC cohorts were assessed; if no DLTs or treatment-related
adverse events (AEs) of grade ≥2 occurred in cycle 1 in the single-patient cohorts, cohorts of three patients with
a twofold dose escalation were then enrolled. If any patient in the single-patient cohorts experienced a DLT or a
treatment-related AE of grade ≥2 in cycle 1, the cohort was expanded to include two additional patients.
As part of an interim data monitoring committee safety review, it was found that all evaluable patients in the
SC cohort had developed antidrug antibodies (ADAs). As a result, the protocol was amended to include topical
glucocorticoids to suppress ADA formation. Clobetasol propionate 0.05% cream was applied to each administration
site over three 7-day periods for the first two treatment cycles (i.e., during days -7–1 of cycle 1 and days 15–21
of cycles 1 and 2). Methylprednisolone aceponate 0.1% cream was also applied to the site daily for the first three
21-day treatment cycles. In addition, the protocol was amended to require the administration of prophylactic
oral and/or IV dexamethasone the evening before the first SC administration of pasotuxizumab, 30 min before
administration on day 1 of cycle 1, optionally on days 2 and 3 of cycle 1 and before restarting pasotuxizumab
treatment after missing ≥2 SC doses. However, this approach had no effect on the development of ADAs. In
August 2016, the development of neutralizing antibodies rendered SC dosing nonviable and the study continued
with the cIV cohort only.
In the SC cohort, pasotuxizumab was administered daily by SC injection over a 21-day cycle, with no breaks
between cycles. The 2-ml syringes for SC administration were prepared by the local pharmacy and administered
either in the clinic by a healthcare professional or at home by the patient. In the cIV cohort, pasotuxizumab was
administered using a portable infusion pump and central venous port system. Treatment cycles were administered
over a 21-day cycle, but patients received 5 weeks of treatment followed by a treatment-free interval of 1 week
(i.e., one treatment-free week at the end of cycles 2 and 4). From cycle 5 onward, patients could receive treatment
over 4 weeks followed by a treatment-free interval of 2 weeks. As with the latter SC cohorts, prophylactic oral or
IV dexamethasone was administered the evening before the first administration of pasotuxizumab, by IV 30 min
before administration on day 1 of cycle 1, optionally oral and/or IV on days 2 and 3 of cycle 1 and before restarting
pasotuxizumab after a break in treatment of ≥2 days (i.e., before cycle 3 and every odd treatment cycle thereafter).
At the discretion of the investigators, concomitant therapy was allowed. Permitted concomitant medications
included clinically indicated low-dose heparin, antihistamines and antacids were permitted, as were denosumab and
bisphosphonates prophylactically or for bone metastases. Paracetamol, metamizole, piritramide and/or short-term
high-dose corticosteroids were permitted for the treatment of cytokine-release syndrome (CRS). Concomitant
palliative and supportive care for patients with any underlying illness were also permitted.
For each patient, treatment continued until tumor progression, unacceptable toxicity, consent withdrawal, or
withdrawal from the study.
Assessments
Adverse events were graded using the Common Terminology Criteria for Adverse Events version 4.03.
To evaluate pharmacokinetic parameters, blood (SC and cIV cohorts) and urine (SC cohort only) samples were
collected. Pharmacokinetic measurements were determined using Phoenix R© WinNonlin R© software (Certara USA,
Inc., NJ, USA).
Immunogenicity of pasotuxizumab was evaluated to assess ADA formation. Briefly, antibody formation was
initially evaluated with an electrochemiluminescence detection-based bridging immunoassay designed to minimize
false negatives. Samples that tested positive were then tested with a confirmatory competitive inhibition assay.
Finally, a cell-based bioassay neutralizing assay was used to detect neutralizing ADAs in positive confirmatory
samples.
Efficacy was assessed according to the Prostate Cancer Clinical Trials Working Group 2 recommendations [27].
Tumor response for measurable lesions was assessed by computerized tomography (CT) and/or magnetic resonance
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imaging according to the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) [28] at screening,
at every fourth cycle, at the end of treatment and as clinically indicated. Nonmeasurable lesions were assessed
according to the RECIST 1.1 criteria for nonmeasurable lesions [28]. Bone metastases were assessed by bone
scintigraphy. Changes in serum PSA levels were assessed predose on days 1, 8 and 15 of cycle 1, at the beginning
of each subsequent cycle and at the end of treatment visit.
PSMA PET/CT imaging was conducted per institutional guidelines outside the study protocol.
Circulating tumor cells were assessed in both the SC and cIV cohorts during treatment. Pharmacodynamic
markers, including cytokines, biomarkers of T-cell activation (i.e., CD69+ and PD-1) and enumeration of T
lymphocyte subsets were conducted before and during treatment.
Statistical analysis
Analyses of pasotuxizumab safety, tolerability, pharmacokinetics and efficacy were descriptive in nature and presented
using summary statistics. The sample size required to adequately determine the MTD depended on the initial dose,
rate of dose escalation and observed dose-toxicity and dose-exposure relationships. Based on experience, the chosen
sample size of one to nine patients per cohort was considered sufficient to fulfill the study objectives. Patients who
received ≥1 dose of pasotuxizumab and had posttreatment safety data available were included in the safety analysis
set; patients who completed pasotuxizumab cycle 1 or discontinued pasotuxizumab during cycle 1 as a result of AEs
or DLTs were included in the MTD evaluation set. Patients who completed the study without any major protocol
violations were included in the pharmacokinetic and pharmacodynamic evaluation set; those with any efficacy data
were included in the efficacy analysis set.
Results
Patients
Overall, 68 patients were enrolled between 2 November 2012 and 18 July 2018, including 45 in the SC cohort
and 23 in the cIV cohort. Of these, 31 and 16, respectively, received ≥1 dose of pasotuxizumab (breakdown of
patients by dose levels is shown in Supplementary Table 1). All treated patients were white, as determined by the
investigators and had a median (range) age of 69 (48–82) years. Additional patient characteristics are summarized
in Table 1. At study entry, 40/47 patients (85%) overall had stage IV disease, the remainder had stage III disease:
25/31 (81%) in the SC cohort and 15/16 (94%) in the cIV cohort. Overall, 28 patients (90%) in the SC cohort
and 15 (94%) in the cIV cohort (Supplementary Table 2) had received ≥1 prior regimen of chemotherapy.
Patients were treated for an overall median time (including treatment interruptions, delays and drug holidays) of
91.0 (maximum, 542.0) days in the SC cohort and 129.0 (maximum, 413.2) days in the cIV cohort. All patients
discontinued treatment; the most common reasons were radiologic disease progression (SC cohort, 21/31 [68%];
cIV cohort, 12/16 [75%]) and AEs not related to disease progression (4/31 [13%] and 1/16 [6%], respectively).
Safety
Treatment-emergent AEs were reported for all patients in the SC and cIV cohorts (Table 2); the most common was
fever (25/31 [81%] and 15/16 [94%], respectively) followed by injection site reaction (24/31 [77%] and 0/16
[0%]), chills (7/31 [23%] and 11/16 [69%]) and fatigue (11/31 [36%] and 5/16 [31%]). AEs by dosing cohort
are summarized in Supplementary Tables 3 and 4. Serious AEs were reported for 22/31 patients (71%) in the SC
cohort and 12/16 (75%) in the cIV cohort. Treatment-emergent AEs of grade ≥3 were reported by 27/31 patients
(87%) in the SC cohort, with the most common being anemia (39%) and decreased lymphocyte count (26%).
Treatment-emergent AEs of grade ≥3 were reported by 13/16 (81%) patients in the cIV cohort, with the most
common being decreased lymphocyte count (44%) and infections and infestations, not otherwise specified (31%).
In the cIV cohort, ≥1 device-related infection (i.e., port catheter infection) was reported in 7/31 patients (23%)
and resulted in ≥1 dose interruption in a total of six patients (19%) overall. These device-related infections were
considered serious in six patients (19%) and resulted in ≥1 dose interruption in five of those patients (16%).
Study drug-related AEs were reported by all patients in the SC cohort; serious study drug–related AEs were
reported by five patients (16%). There were no deaths from study drug-related AEs. DLTs were experienced by
three patients (10%; n = 1 each in the 144.0-μg [grade 3 confusion and grade 2 fever], 172.0-μg [grade 3 injection
site reaction] and 172.0-μg + glucocorticoids [grade 3 hypotension and grade 3 fatigue] dose cohorts). Based on
safety evaluations, the MTD for the SC dose was determined to be 172.0 μg daily.
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White race, n (%)† 31 (100) 16 (100) 47 (100)
Ethnicity, n (%)†
Not Hispanic/Latino 28 (90) 16 (100) 44 (94)
Not reported 3 (10) 0 3 (6)
Age, median (range), y 69 (48–82) 69 (57–78) 69 (48–82)
Clinical characteristics at initial diagnosis, n (%)
AJCC grading score with Gleason
Grade 1 1 (3) 0 1 (2)
Grade 2 9 (29) 3 (19) 12 (26)
Grade 3–4 20 (65) 12 (75) 32 (68)
No grade 1 (3) 1 (6) 2 (4)
Gleason score at initial diagnosis
6 1 (3) 0 1 (2)
7 16 (52) 4 (25) 20 (43)
8 2 (7) 6 (38) 8 (17)
9 11 (36) 5 (31) 16 (34)
Missing 1 (3) 1 (6) 2 (4)
Clinical characteristics at study entry, n (%)
Histology of prostate cancer
Adenocarcinoma NOS 29 (94) 13 (81) 42 (89)
Glandular intraepithelial neoplasia (grade III) 1 (3) 3 (19) 4 (9)
Papillary adenocarcinoma 1 (3) 0 1 (2)
Status of primary tumor
Resected, no residual, or recurrent tumor 11 (36) 7 (44) 18 (38)
Resected, residual, or recurrent tumor 6 (19) 3 (19) 9 (19)
Resected, status of residual tumor unknown 3 (10) 2 (13) 5 (11)
Unresected 11 (36) 4 (25) 15 (32)
TNM stage
I 0 0 0
II 2 (7) 0 2 (4)
III 3 (10) 1 (6) 4 (9)
IV 25 (81) 15 (94) 40 (85)
Missing 1 (3) 0 1 (2)
ECOG performance status, n (%)
0 26 (84) 9 (56) 35 (74)
1 5 (16) 7 (44) 12 (26)
†Race/ethnicity were determined by the investigators.
AJCC: American Joint Committee on Cancer; cIV: Continuous intravenous; ECOG: Eastern Cooperative Oncology Group; NOS: Not otherwise specified; SC: Subcutaneous; TNM: Tumor
node metastasis.
In the cIV cohort, study drug-related AEs were reported by 15 patients (94%). A serious study drug-related
AE (grade 3 fatigue) was reported for one patient (6%) in the 20-μg/d group and was the only DLT observed.
Drug-related, nonserious CRS was reported for three patients (19%); two were grade 2 and one was grade 3. No
relevant organ toxicities were observed, although treatment-emergent increases in alanine aminotransferase (grade
1, 44%) and aspartate aminotransferase (grade 1, 44%; grade 2, 19%) did occur. There were no study drug-related
deaths. Because of a sponsor change, the study was stopped early and the MTD for the cIV cohort was not reached.
Immunogenicity
Of the 31 patients who received ≥1 dose of SC pasotuxizumab, 30 (96.7%) had treatment of sufficient duration to
assess formation of ADAs. All 30 patients developed ADAs, with a median onset of 22 days after treatment initiation
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Table 2. Adverse events†.






Any treatment-emergent AE 31 (100) 16 (100) 47 (100)
Serious 22 (71) 12 (75) 34 (72)
Leading to dose modification‡ 13 (42) 8 (50) 21 (45)
Leading to permanent discontinuation of study drug 7 (23) 1 (6) 8 (17)
Any study drug–related AE 31 (100) 15 (94) 36 (77)
Worst grade
1 or 2 16 (52) 5 (31) 21 (45)
3 8 (26) 7 (44) 25 (53)
4 7 (23) 3 (19)
5 0 0 0
Serious 5 (16) 1 (6) 6 (13)
Leading to dose modification‡ 5 (16) 1 (6)§ 6 (13)
Leading to permanent discontinuation of study drug 2 (7) 0 2 (4)
Study drug–related AEs of any grade occurring in 10% of
patients during either SC or cIV treatment
Fever 25 (81) 15 (94) 40 (85)
Injection site reaction 24 (77) 0 24 (51)
Chills 7 (23) 11 (69) 18 (38)
Fatigue 11 (36) 5 (31) 16 (34)
Skin and subcutaneous tissue disorders, other 10 (32) 0 10 (21)
Investigations, other 8 (26) 2 (13) 10 (21)
General disorders and administrative site conditions, other 7 (23) 2 (13) 9 (19)
Lymphocyte count decreased 8 (26) 7 (44) 15 (32)
Pruritus 5 (16) 0 5 (11)
Nausea 4 (13) 1 (6) 5 (11)
Vomiting 4 (13) 1 (6) 5 (11)
Diarrhea 4 (13) 1 (6) 5 (11)
Platelet count decreased 3 (10) 2 (13) 5 (11)
Hypophosphatemia 3 (10) 2 (13) 5 (11)
Cytokine release syndrome 0 3 (19) 3 (6)
Infections and infestations 1 (3) 2 (13) 3 (6)
White blood cell count decreased 1 (3) 2 (13) 3 (6)
Dyspnea 0 2 (13) 2 (4)
†AEs were coded according to the Preferred Terms of the Medical Dictionary for Regulatory Activities, version 20.0. Severity of AEs was graded according to the National Cancer Institute
Common Terminology Criteria for Adverse Events, version 4.03.
‡Modifications include delays, interruptions and reduction.
§A study drug–related AE of grade 3 fatigue was reported for one patient in the 20-μg/d cohort.
AE: Adverse event; cIV: Continuous intravenous; SC: Subcutaneous.
(Supplementary Table 5). Neutralizing ADAs were detected in 28 of these 30 evaluable patients; these ADAs affected
exposure with no associated adverse events. Maximum ADA titers did not correlate with dose. ADAs were sustained
through the end of sampling, in other words, ADAs were not transient. Topical glucocorticoid treatment did not
have any effect on the development of neutralizing ADAs. Owing to the high rate of ADA development and the lack
of response to ADA mitigation measures, further evaluation of the SC route of administration was discontinued.
At the time of study discontinuation, ADAs had not been detected in any patients in the cIV cohort (Supplementary
Table 6).
Pharmacokinetics
Following SC pasotuxizumab administration (doses of 18–172 μg, including glucocorticoids with the two higher
doses), maximum serum concentration (Cmax) of between 0.18 and 1.70 μg/l was reached between 5.95 and 23.5 h
postdose on day 1 of cycle 1 and Cmax of between 0.196 and 1.83μg/l was reached between 3.95 and 6.08 h postdose
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on day 15 of cycle 1 (Supplementary Table 7). As noted above, ADA development was associated with decreased
exposure to the study drug. Accumulation was marginal following repeated dosing and dose proportionality was
observed across all dose cohorts. Pasotuxizumab was below the quantification limit (0.44 μg/l) in all urine samples
at 0–12 or 12–24 h after the first SC injection in doses ranging from 36 to 172 μg daily.
Following cIV pasotuxizumab administration, the mean plasma steady-state serum pasotuxizumab concentra-
tions increased approximately dose proportionally (Supplementary Figure 1). Steady-state pasotuxizumab serum
concentrations were reached within approximately 1 day after initiating pasotuxizumab IV infusion (Supplementary
Figure 2).
Efficacy
In the SC cohort, reductions in PSA >50% relative to baseline were observed for the 72- and 172-μg cohorts, but
there was no clear relationship between dose and response (Figure 1A). The median (range) best overall PSA response
assessed as percentage change in PSA levels from baseline was -24.7% (-87.4%–28.7%; Figure 2B). Reductions in
PSA >50% relative to baseline were observed in nine patients (30%) in the SC cohort and were not dose related,
as noted above (Figure 1B). PSA responses typically occurred within the first two treatment cycles; however, they
were not sustained, most likely because of the development of ADAs. Five of the nine patients with PSA reductions
>50% were treated with 172 μg (with and without glucocorticoids); the remaining four patients were in the 18-,
36-, 72- or 144-μg dose cohorts. One patient had an initial unconfirmed response of >50% reduction in liver
metastasis in parallel to the reduction in PSA levels of 85% (from 309 μg/l at baseline to a minimum of 45 μg/l).
In the cIV cohort, antitumor activity as indicated by PSA serum level decline was dose dependent, with a
median best PSA change from baseline of -22.0, -37.7 and -54.9% for the 20-, 40- and 80-μg/d dose cohorts,
respectively, and -20.6% overall (Figure 2A). In the cIV cohort, 14 patients showed a decline in PSA during
study treatment (Figure 2B). A >50% decline in PSA was seen in three of nine patients at the higher dose levels:
n = 1 each in the 20-μg/d (-75.0%), 40-μg/d (-77.7%) and 80-μg/d (-96.7%) cohorts (Figure 2B). Two patients
had a long-term PSA response. Patient 13 (40 μg/d) had a >50% reduction in serum PSA for approximately
50 weeks (baseline, 39.2 μg/l; best PSA response, 9.3 μg/l; Supplementary Figure 3) and had stable disease with
337 days to tumor progression. Patient 15 (80 μg/d) had even more marked reduction in serum PSA (baseline,
196.0 μg/l; best PSA response, 6.4 μg/l), with near-complete regression of lymph node lesions and bone metastases
as assessed by PSMA PET/CT and 500 days to tumor progression (see Supplemental Appendix for more detail).
Before treatment, accumulation of the PSMA-specific radioligand in the skeleton and pelvic lymph nodes indicated
extensive metastatic disease (Figure 3). Within 43 days of beginning treatment, the extent of PSMA-expressing
tumor was significantly reduced, with negligible evidence of tumor after 85 days. A profound metabolic and
morphologic response in retroperitoneal lymph node metastases was recorded as early as 3 months after treatment
initiation. At 16 months, progressive disease with multiple new PSMA-positive osseous lesions was recorded (with
ongoing metabolic near-complete remission of lymph node metastases).
In the SC cohort, 18 patients had measurable target lesions at baseline. Of these, no patient had a complete or
partial response per RECIST 1.1; five patients (17%) had stable disease. The maximum reduction in tumor size
from baseline for 14 patients is shown in Figure 4. Across the 30 evaluable patients in the SC cohort, the median
(range) time to tumor progression was 92 (43–505) days.
Of the 11 RECIST-measurable patients in the cIV cohort (Supplementary Table 2), the best overall response
according to RECIST 1.1 was stable disease in three patients and noncomplete response/nonprogressive disease
in another three patients (Table 3). In the cIV cohort (n = 16), the median (range) time to progression for the 13
patients with progressive disease was 98 (68–500) days and 165, 84, 84, 168 and 292 days in the 5-, 10-, 20-, 40-
and 80-μg/d groups, respectively.
Biomarkers
For the SC cohort, decreased lymphocyte count was reported for eight patients (26%). In this cohort, CTC counts
after cycles 1, 2 and 4 did not change in a dose-related manner (Supplementary Figure 4). Additionally, CD69+
and PD-1 assessment showed early signs of T-cell activation, with CD69+ activation beginning on day 2 of cycle 1
and continuing through day 8. PD-1 activation began on day 3 of cycle 1 and was less pronounced (Supplementary
Figure 5).
For the cIV cohort, decreased lymphocyte count was reported for seven patients (44%); however, recovery of
lymphocyte count was complete or almost complete by day 15 (Supplementary Figure 6). The CTC values after
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Figure 1. Best PSA response after pasotuxizumab treatment in the subcutaneous cohort. Best PSA response after treatment initiation
for each dose cohort (A) and for individual patients (B), shown as percentage change from baseline.
GC: Glucocorticoid.
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Figure 2. PSA response after treatment with pasotuxizumab in the continuous intravenous cohort. Best PSA
response after treatment initiation, shown as mean percentage change from baseline for each dose cohort (A) and
for individual patients (B).
cycles 1, 2 and 4 for the cIV cohort are presented in Figure 5. At doses ≥20 μg/d, a dose-dependent decrease in
CTC values was observed posttreatment that was paralleled by increases in CD69+ and PD-1 on CD8 T cells
(Figure 6A & B). Patient 15, who was treated at the highest dose level and had normalization of lymph node lesions
and marked regression of bone metastases, also had a marked CTC response.
Discussion
Overall, pasotuxizumab showed evidence of early efficacy when evaluated in this Phase I, dose-escalation study in
patients with advanced CRPC. All patients experienced ≥1 AE of any grade and more than half experienced ≥1
drug-related AE of grade ≥3; fever and injection site reactions were the most common AEs in the SC cohort; with
fever and chills the most common in the cIV cohort. The MTD for SC administration of pasotuxizumab was
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Pre-therapy 3 months 4 months 8 months 16 months
Pre-therapy 3 months 4 months 8 months 16 months
Figure 3. Summary of outcomes in patient 15 after treatment with pasotuxizumab. For patient 15, a compilation of
representative PSMA PET/CT 3D whole-body views (A) and transaxial 68Ga-PSMA PET (top row (B); inserts, PET
maximum intensity projections), CT (middle row [B]) and fused PET/CT (bottom row [B]) slices at different time points
during treatment with pasotuxizumab.
CT: Computed tomography; 68Ga: Gallium-68; PET: Positron emission tomography.














5 3 0 1 1 0 1
10 4 0 1 1 1 1
20 3 1 0 2 0 0
40 4 1 1 1 0 1
80 2 1 0 1 0 0
† Included patients who did not have a postbaseline tumor assessment but who discontinued because of a drug-related toxicity, death, progression by clinical judgment before disease
was re-evaluated and were therefore considered evaluable, or who withdrew (patient was considered a nonresponder).
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Figure 5. Mean circulating tumor cell counts by dose cohort in the continuous intravenous cohort. Blood samples
for the assessment of CTCs were collected before infusion start (cycle 1, day 1); at cycle 2, day 1; and at cycle 4, day 1.
Numbers of CTCs were determined in 7.5 ml of whole blood using the CellSearch R© assay that enumerates CD45-,
EpCAM+ and cytokeratins 8+, 18+ and 19+ (CellSearch Epithelial Cell Kit/CellSpotter™ Analyzer; Menarini Silicon
Biosystems Inc., Huntington Valley, PA, USA). Sample processing and analyses were performed according to the
manufacturer’s instructions. Data shown are for all patients with valid biomarker data. The mean number of CTCs
increased over time in patients receiving pasotuxizumab 5 and 10 μg/d and decreased from cycle 1 through 4 for
patients receiving pasotuxizumab 20 and 40 μg/d.
CTC: Circulating tumor cell.
determined to be 172.0 μg daily; however, the cIV cohort was stopped after enrolment of 16 patients and before
the MTD was reached because of a change in study sponsorship.
Following SC pasotuxizumab administration, Cmax was reached 5.95–23.5 h postdose on day 1 of cycle 1 and
between 3.95–6.08 h on day 15 of cycle 1. In human prostate cancer xenograft models, the terminal half-life of
pasotuxizumab was approximately 8 h [26]. In nonhuman primates, a similar half-life (about 7 h) was calculated
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Figure 6. Flow cytometric analysis of activation of CD8+ T cells during cycle 1 in the continuous intravenous cohort.
Activation of T cells as assessed by expression of CD69 (A) peaked at day 3 of cycle 1; expression of PD-1 (B) was
elevated from day 3 to 15 of cycle 1. Presented as the percentage (SD) of CD8+ cells in the peripheral blood at each
time point expressing CD69 and PD-1.
PD-1: Programmed death 1; SD: Standard deviation.
after SC administration; after IV administration, the half-life was 1 and 3 hours. This pharmacokinetic profile
allowed for daily SC administration with marginal accumulation and cIV administration.
All patients who received SC pasotuxizumab for >1 treatment cycle developed ADAs, likely due to the high
localized concentrations of pasotuxizumab, uptake of pasotuxizumab by dendritic cells and subsequent presentation
to the lymphocytes in the local lymph nodes. In an attempt to avoid the formation of ADAs by antigen-presenting
cells localized in the skin and to reduce local skin immune reactions, the protocol was amended to include
concomitant administration of topical glucocorticoid, in addition to systemic corticosteroids, to suppress antigen-
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presenting cells in new SC cohorts receiving 144 and 172 μg. However, this approach had no effect on the
development of ADAs, which did affect exposure but were not associated with adverse events. Therefore, enrollment
in the SC cohort was discontinued, and focus was shifted to evaluation of pasotuxizumab administered by cIV
infusion. No ADAs were detected in the cIV cohort. As expected this change in the route of administration
appeared to have affected ADA development, due in part to the lower local drug concentrations and also because
IV administration of biotherapeutics >20 kDa may result in decreased exposure of drug to the lymphatic system
than occurs with SC administration [29].
Pasotuxizumab showed signs of clinical response in the SC and cIV cohorts. In the SC cohort, the median
best overall PSA response was a decline of 25%, with about a third of patients showing an initial >50% decline
in PSA values. PSA levels typically reverted to levels higher than baseline over time, most likely related to the
reduced exposure to pasotuxizumab following the development of neutralizing ADAs. Although no patients
showed complete or partial responses by RECIST 1.1 criteria, nearly one fifth of patients experienced stable disease,
with time without progression ranging from 0 to 11 months in these patients; median time to progression was
approximately 3 months across evaluable patients.
In the cIV cohort, moderate lymphocyte redistribution at the start of therapy indicated T-cell engagement by
pasotuxizumab and a dose-dependent reduction in CTCs was observed; dose-dependent reductions were observed in
serum PSA levels across the doses tested, with about a third of patients in the 20-, 40- and 80-μg/d cohorts showing
a >50% decline in PSA. For the two long-term PSA responders, tumor progression was observed 11–17 months
after pasotuxizumab initiation.
Of the 11 RECIST-measurable patients in the cIV cohort, the best overall response according to RECIST 1.1
was stable disease in three patients and noncomplete response/nonprogressive disease in another three patients.
In patients with progression, median time to progression was 98 days and 165, 84, 84, 168 and 292 days in the
5-, 10-, 20-, 40- and 80-μg/d groups, respectively. Dose-dependent reductions in CTC were observed at doses
≥20 μg/d. One patient treated at the highest dose level had a near-complete remission and experienced clinical
benefit with a substantial improvement in quality of life for almost 19 months. The patient experienced grade 3
CRS (cycle 1, day 1 lasting to day 2) with fever ≤40◦C, mild vomiting and low-grade diarrhea. Symptoms were
managed with IV hydration and antipyretic therapy and were fully reversible without pasotuxizumab interruption.
Pasotuxizumab accumulation was minimal following repeated dosing; dose proportionality was observed across
all patient cohorts.
Device-related infections occurred in about a quarter of patients in the cIV cohort, affecting their health
and treatment experience, with 86% of those who experienced such infections requiring ≥1 dose interrup-
tion. For optimal outcomes, a greater understanding of the underlying cause of these infections is required and
management/prevention of these infections will need to be improved. In the cIV cohort, CRS-associated symptoms
occurred in three patients within the first few days after treatment start and were manageable and fully reversible;
there were no organ-specific toxicities.
Potential in prostate cancer
Patients with mCRPC need more effective treatments. BiTE immune therapies have been found to be of value in
the treatment of hematologic cancers and could also be of value in patients with solid tumors, such as prostate
cancer [30]. As a BiTE immune therapy, pasotuxizumab is designed to engage a patient’s own T cells to PSMA
expressing cells [30]. Indeed, the results reported here suggest that pasotuxizumab administered by cIV infusion
may provide durable clinical benefit even in extensively pretreated patients with prostate cancer. In the cIV cohort,
a dose-dependent decline in PSA levels was observed in 14 patients, providing proof of concept of the value of
BiTE immune therapies in prostate cancer. AMG 160, a fully human half-life extended BiTE immune therapy
that is administered by short IV infusion, is currently under development for mCRPC [31] and may provide further
support for the role of BiTE immune therapy in prostate cancer.
There is great interest and some promising reports for treatment with 177Lu-PSMA-617 [16–19,32,33]. Patients
who were previously treated with 177Lu-PSMA-617 were not excluded from this study. Of interest, before receiving
pasotuxizumab treatment, the pasotuxizumab long-term responder (patient 15) did not respond to 177Lu-PSMA
therapy administered over a period of 6 months. Resistance to 177Lu-PSMA-617 occurs through standard DNA
repair mechanisms or multidrug resistance pathways [34], and reduced clinical activity was observed in patients
previously treated with chemotherapy [35]. The mechanism of action of pasotuxizumab is based on engaging T-cell-
mediated tumor cell killing and is not related to DNA damage or repair. Therefore, pasotuxizumab treatment is
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not anticipated to be cross-resistant with standard chemotherapy, radiation therapy, or therapy with radioisotopes;
as observed, patient 15 responded to pasotuxizumab despite having no response to 177Lu-PSMA.
This study had a number of limitations. The development of ADAs following SC administration had an effect
on the pharmacokinetic profile and the efficacy of the immune therapy. Subsequently, the less immunogenic route
of administration, cIV infusion, was evaluated in a relatively small number of patients. Additionally, because of a
sponsor change, the cIV study was stopped early, MTD was not reached for the cIV cohort and not all planned
assessments were undertaken.
Conclusion
This is the first clinical report showing that a BiTE immune therapy administered as monotherapy can be efficacious
in prostate cancer while also demonstrating that BiTE monotherapy can be effective in solid tumors. We consider
the early responses observed among patients with advanced CRPC to be encouraging. A continuation of the dose-
escalation study that determines the MTD of pasotuxizumab administered by cIV infusion could be informative,
especially given the promising results observed in the cIV cohort of the current study [36]. A first-in-human study
of AMG 160, a half-life extended BiTE immune therapy that also binds PSMA, is currently underway [37]. The
results of that study will further elucidate the potential of BiTE immune therapies to treat CRPC [31].
Summary points
• PSMA is highly expressed in prostate cancer and its metastates compared with normal tissue and has been
validated as a target for therapy in metastatic castration-resistant prostate cancer (CRPC).
• Bispecific T-cell engager (BiTE R©) immune therapies have been approved for hematologic cancers over the last
decade, but their role in solid tumors such as CRPC is unclear.
• Pasotuxizumab (AMG 212 or BAY 2010112), a BiTE immune therapy designed to engage CD3 on T cells and PSMA
on prostate cancer cells and to activate a patient’s own T cells to eliminate PSMA-expressing prostate cancer cells,
has demonstrated preclinical antitumor activity.
• Subcutaneous administration of pasotuxizumab was associated with the development of anti-drug antibodies;
antidrug-antibody development was not observed with cIV infusion.
• Dose-dependent decline in PSA levels was observed in the cIV cohort, providing proof of concept of the value of
BiTE immune therapies in prostate cancer.
• Two patients had long-term PSA responses; one patient had long-term stable disease and the other patient had
near-complete regression of lymph node lesions and bone metastases, with 500 days to disease progression.
• This first-in-human study demonstrated the safety and preliminary efficacy of BiTE monotherapy in the treatment
of CRPC.
• Further clinical studies are required to fully elucidate the role of BiTE immune therapies in the treatment of CRPC.
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